Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy

Abstract Background Poliovirus receptor (PVR) and its receptor system, including TIGIT, CD226, and CD96, play a pivotal role in orchestrating tumor immune evasion. Upon engagement with PVR on tumor cells, CD96 exerts inhibitory effects on the function of T cells and NK cells, thereby fostering tumor...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiangrui Zhang, Lihan Zhang, Beibei Li, Qingchao Wang, Peixin Chen, Ranran Shi, Xiuman Zhou, Xiaoshuang Niu, Wenjie Zhai, Yahong Wu, Wenhui Shen, Xiaowen Zhou, Wenshan Zhao
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Biology
Subjects:
CD96
PVR
Immune checkpoint inhibitor
Small molecule
Cancer immunotherapy
Online Access:https://doi.org/10.1186/s12915-025-02132-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12915-025-02132-y

Similar Items